ClinicalTrials.gg
RecruitingNCT04061135Updated Mar 17, 2026

Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders

An interventional study of Response Inhibition and Deep Brain Stimulation in Parkinson's disease in Movement Disorders, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 203 studies in Movement Disorders with a site in United States — 52 open to participants now, 59 under way, 2 of them phase 3. Movement Disorders · United States.

Planned enrollment
43rd of 117
90 · median 50
Started
2019
with 9 others
No phase
50 of 203
21 open now
Primary completion
2028-03
later than 32 of 55 live
Registered
110th of 203
by date

Among the 203 studies in Movement Disorders with a site in United States, this one is the 43rd largest by planned enrollment of the 117 interventional ones that give a count, is one of 10 that started in 2019, is one of 50 with no phase, reaches primary completion later than 32 of the 55 other live ones, and was the 110th registered.

Movement Disorders

373 studies on the registry are indexed under Movement Disorders; 104 are open to participants now.

Browse Movement Disorders studies →

Open to participants now

52 of the 203 studies in Movement Disorders with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Movement Disorders studies recruiting now, 30 (40%) set no upper age limit and 18 (24%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Movement Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower processing speeds. The investigators are interested in the brain activity associated with these motor and non-motor symptoms, and propose to investigate changes in brain activity while the investigators perform recordings of the surface and deep structures of the brain, in addition to the typical recordings the investigators perform, during routine deep brain stimulation (DBS) surgery.

Read the detailed description

Movement disorders are a prominent cause of disability worldwide. In the United States, it is estimated that more than 4 million people suffer from Parkinson's disease (PD), essential tremor (ET), and dystonia, making them some of the most prevalent of neurologic disorders. Of these, PD is the most common, and is primarily characterized by tremor, rigidity, and bradykinesia. However, though primarily characterized by motor symptoms, many patients also have prominent non-motor features, including depression and cognitive impairment, with deficiencies in processing speed, memory, attention, and learning. Some of the most debilitating cognitive deficiencies include deficits in goal-directed response selection and response inhibition, language, and/or speech difficulties, all of which substantially contribute to reduced quality of life.

Unfortunately, these features of movement disorders are less well-studied and lack effective treatment options, necessitating that new treatments be investigated. Deep brain stimulation (DBS), while a highly effective treatment for the cardinal features of PD, is essentially ineffective for, and can even worsen other cognitive domains, and there are few studies currently investigating how different parameters of DBS may improve these symptoms. In addition, speech abnormalities are common with Parkinson's disease and DBS can sometimes worsen speech problems. These impairments consists primarily of hypophonia, but cognitive deficits can result in actual language disturbance. It is often difficult to know whether the speech problems are related to language processing or articulation (related to the movement disorder). In an effort to begin addressing these questions, we propose to study motor and non-motor symptoms in patients with movement disorders, and to correlate movement and cognition with underlying neural electrophysiology.

03

Conditions studied

  • Movement Disorders

Keywords

  • Parkinson's disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible for DBS surgery based on multi-disciplinary consensus review
  • Have a diagnosis of Parkinson's disease or Essential Tremor
  • A minimum of 18 years of age
  • Willingness to participate in the paradigms described in the protocol

Exclusion criteria

Exclusion Criteria:

  • Inability to provide full and
  • Are not surgical candidates due to co-morbid conditions or pregnancy
  • Have not undergone an adequate trial of conservative medical management
  • Have a clinical presentation for which DBS surgery is not indicated
  • Are not able to participate in study-related activities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Treatment

    Parkinson's Disease Patients receiving DBS electrodes

    Procedure: Response Inhibition and Deep Brain Stimulation in Parkinson's disease

  • No intervention
    Control

    Control subjects will be non-Parkinson's Disease patients with essential tremor

Interventions

  • ProcedureResponse Inhibition and Deep Brain Stimulation in Parkinson's disease

    After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.

06

What researchers measure

Primary outcomes

  1. Accuracy via Simon Task (% correct)

    In the Simon task, participants are instructed to respond with a right or left button press (Right = Red, Left = Blue) according to how a word is printed on a screen ("RED" or "BLUE"), regardless of the color in which the word is printed. This is a measurement of accuracy (% correct, ranging from 0-100, with higher scores indicating better performance)

    Time frame: Baseline

  2. Response times via Simon Task (sec)

    In the Simon task, participants are instructed to respond with a right or left button press according to the word "RIGHT" or "LEFT" that appears on a screen, regardless of where on the screen it actually appears. This is a measurement response times (continuous measure, from 0-4000 milliseconds) between correct and incorrect responses.

    Time frame: Baseline

  3. Simon Effect on Response times (sec)

    Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in response times between congruent and incongruent trials

    Time frame: Baseline

  4. Simon Effect on Accuracy (% correct)

    Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in accuracy between congruent and incongruent trials

    Time frame: Baseline

  5. UPDRS 3 motor score (0-108)

    Participants will undergo motor evaluation using the validated United Parkinson's disease Rating Scale (UPDRS) part 3

    Time frame: Baseline

  6. Dementia Rating Scale Score (0-144 points)

    Participants will undergo neuropsychological testing as part of routine care, including the Dementia Rating Scale

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Mar 2028, 102 months after the start.

Of 83 non-industry interventional studies with no phase under Movement Disorders, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 80. This study's planned 102 months is above that.

Counting every sponsor, half of 85 studies reached it within 33 months; a quarter within 11 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2019
First posted
Aug 19, 2019
StartActual
Sep 1, 2019
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2029
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04061135
Responsible party
J. Nicole Bentley (Principle Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Aug 19, 2019
Start date
Sep 1, 2019
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Mar 17, 2026

Study contacts

Nicole Bentley, MD
Contact
jbentley@uabmc.edu
205-975-0011
Nicole Bentley, MD
principal investigator · University of Alabama at Birmingham

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion